BBI Stock Price, News & Analysis

Brickell Biotech, Inc. (Nasdaq: BBI) has successfully closed its public offering of 12,983,871 shares of common stock at a price of $0.62 per share, generating approximately $8.05 million in gross proceeds. The offering included the underwriter's full option to purchase an additional 1,693,548 shares. Funds will support research, clinical trials, and general corporate purposes. H.C. Wainwright & Co. served as the sole book-running manager. This offering was conducted under a previously filed registration statement with the SEC.

Brickell Biotech, Inc. (Nasdaq: BBI) announced a public offering of 11,290,323 shares of common stock at $0.62 per share, expected to close around July 22, 2021. The gross proceeds of approximately $7.0 million will be allocated for research and development, including clinical trials, working capital, and general corporate purposes. The offering includes a 30-day option for the underwriter to purchase an additional 1,693,548 shares. The shares are being offered under a shelf registration statement effective since March 17, 2021.

Brickell Biotech, Inc. (Nasdaq: BBI) has entered into an underwriting agreement with H.C. Wainwright & Co. to sell 8,064,517 shares of common stock at $0.62 per share. The public offering, expected to close around July 22, 2021, is projected to generate approximately $5.0 million in gross proceeds. A 30-day option for the underwriter to buy an additional 1,209,677 shares is included. Proceeds will support research and development, clinical trials, and general corporate purposes, bolstering Brickell's focus on innovative therapeutics for skin diseases.

Brickell Biotech, a clinical-stage pharmaceutical company, has announced its participation in one-on-one investor meetings at the William Blair Biotech Focus Conference 2021, happening virtually from July 14-15. The company focuses on developing innovative therapeutics for debilitating skin diseases, particularly its lead asset, sofpironium bromide, aimed at treating hyperhidrosis. Brickell's management team boasts extensive experience in product development and commercialization from their roles in major pharmaceutical companies.

Brickell Biotech, a clinical-stage pharmaceutical company, announced the completion of enrollment in its Phase 3 pivotal studies, Cardigan I and Cardigan II, for sofpironium bromide gel, 15% targeting primary axillary hyperhidrosis. Approximately 350 subjects participated in each study. Topline results are expected in Q4 2021, which may support a New Drug Application in the U.S. for sofpironium bromide gel.

Brickell Biotech (Nasdaq: BBI) has announced the initiation of a Phase 1 clinical study in Japan by its partner, Kaken Pharmaceutical, to evaluate the pharmacokinetics of sofpironium bromide gel for treating primary palmoplantar hyperhidrosis (PPH). In Japan, 5.33% of the population suffers from palmar hyperhidrosis, with no approved topical treatments available. Additionally, Brickell is conducting U.S. Phase 3 trials for its sofpironium bromide gel, 15%, targeting primary axillary hyperhidrosis, with topline results expected in Q4 2021.

Brickell Biotech has announced the publication of long-term safety and efficacy results from a Phase 3 study of sofpironium bromide gel in Japan for treating primary axillary hyperhidrosis in the Journal of Dermatology. This follows Kaken Pharmaceutical's regulatory approval in September 2020 and commercial launch in November 2020. Brickell also reports progress in its U.S. Phase 3 studies, Cardigan I and II, with topline results expected in Q4 2021. Sofpironium bromide aims to offer a best-in-class treatment for a condition affecting millions.

Brickell Biotech (BBI) announced the completion of enrollment in its Phase 3 Cardigan I study and over 70% enrollment in the Cardigan II study, with topline results expected in Q4 2021. The company reported Q1 2021 revenue of approximately $17,000, down from $1 million in Q1 2020, mainly due to changes in sales and collaboration revenue. Research and development expenses rose to $6.1 million, driven by increased clinical costs. The net loss for Q1 2021 was $9 million, up from $4.1 million in the prior year. The company ended Q1 2021 with $34.8 million in cash.

Brickell Biotech, Inc. (Nasdaq: BBI) announced it will report its first-quarter financial results for the period ending March 31, 2021, on May 13, 2021, after market close.

Management will host a conference call and webcast at 4:30 PM ET the same day to discuss results and corporate highlights. The company focuses on developing innovative therapeutics for skin diseases, particularly its lead asset, sofpironium bromide, for hyperhidrosis treatment.